Development of a novel approach, the epigenome-based outlier approach, to identify tumor-suppressor genes silenced by aberrant DNA methylation

Cancer Letters

Volumn 322, Issue 2, 2012, Pages 204-212

  Kikuyama, Mizuho ^a,b   Takeshima, Hideyuki ^a   Kinoshita, Takayuki ^c   Okochi Takada, Eriko ^a   Wakabayashi, Mika ^a   Akashi Tanaka, Sadako ^c   Ogawa, Toshihisa ^b   Seto, Yasuyuki ^b   Ushijima, Toshikazu ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Aberrant DNA methylation; Epigenetics; Tumor suppressor gene

Indexed keywords

BRCA1 PROTEIN; HISTONE H3; PROTEIN MLH1; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RNA POLYMERASE II;

ABERRANT DNA METHYLATION; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL LEVEL; COLON CANCER; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DNA MICROARRAY; DZIP1 GENE; ENZYME BINDING; EPIGENETICS; EPIGENOME BASED OUTLIER APPROACH; FBN2 GENE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE SILENCING; GENOME ANALYSIS; HOXA5 GENE; HOXC9 GENE; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; MLH1 GENE; ONCOGENE; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROMOTER REGION; RASSF1A GENE; TUMOR SUPPRESSOR GENE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BREAST NEOPLASMS; CELL LINE; CPG ISLANDS; DNA METHYLATION; EPIGENOMICS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENOME-WIDE ASSOCIATION STUDY; HUMANS; PROMOTER REGIONS, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 84861673768     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.03.016     Document Type: Article

References (59)

1. Lin J.C., Jeong S., Liang G., Takai D., Fatemi M., Tsai Y.C., Egger G., Gal-Yam E.N., Jones P.A. Role of nucleosomal occupancy in the epigenetic silencing of the MLH1 CpG island. Cancer Cell 2007, 12:432-444.
2. Herman J.G., Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 2003, 349:2042-2054.
3. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007, 128:683-692.
4. Kondo Y. Epigenetic cross-talk between DNA methylation and histone modifications in human cancers. Yonsei Med. J. 2009, 50:455-463.
5. Laird P.W., Jaenisch R. The role of DNA methylation in cancer genetic and epigenetics. Annu. Rev. Genet. 1996, 30:441-464.
6. Ushijima T. Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer 2005, 5:223-231.
7. Esteller M. Epigenetics in cancer. N. Engl. J. Med. 2008, 358:1148-1159.
8. Toyota M., Suzuki H., Yamashita T., Hirata K., Imai K., Tokino T., Shinomura Y. Cancer epigenomics: implications of DNA methylation in personalized cancer therapy. Cancer Sci. 2009, 100:787-791.
9. Okochi-Takada E., Nakazawa K., Wakabayashi M., Mori A., Ichimura S., Yasugi T., Ushijima T. Silencing of the UCHL1 gene in human colorectal and ovarian cancers. Int. J. Cancer 2006, 119:1338-1344.
10. Suzuki H., Gabrielson E., Chen W., Anbazhagan R., van Engeland M., Weijenberg M.P., Herman J.G., Baylin S.B. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat. Genet. 2002, 31:141-149.
11. Yamashita K., Upadhyay S., Osada M., Hoque M.O., Xiao Y., Mori M., Sato F., Meltzer S.J., Sidransky D. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2002, 2:485-495.
12. Yamashita S., Hosoya K., Gyobu K., Takeshima H., Ushijima T. Development of a novel output value for quantitative assessment in methylated DNA immunoprecipitation-CpG island microarray analysis. DNA Res. 2009, 16:275-286.
13. Yamashita S., Tsujino Y., Moriguchi K., Tatematsu M., Ushijima T. Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2'-deoxycytidine treatment and oligonucleotide microarray. Cancer Sci. 2006, 97:64-71.
14. Takeshima H., Yamashita S., Shimazu T., Niwa T., Ushijima T. The presence of RNA polymerase II, active or stalled, predicts epigenetic fate of promoter CpG islands. Genome Res. 2009, 19:1974-1982.
15. De Smet C., Loriot A., Boon T. Promoter-dependent mechanism leading to selective hypomethylation within the 5' region of gene MAGE-A1 in tumor cells. Mol. Cell. Biol. 2004, 24:4781-4790.
16. Juttermann R., Li E., Jaenisch R. Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc. Natl. Acad. Sci. USA 1994, 91:11797-11801.
17. Palii S.S., Van Emburgh B.O., Sankpal U.T., Brown K.D., Robertson K.D. DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol. Cell. Biol. 2008, 28:752-771.
18. Abe T., Toyota M., Suzuki H., Murai M., Akino K., Ueno M., Nojima M., Yawata A., Miyakawa H., Suga T., Ito H., Endo T., Tokino T., Hinoda Y., Imai K. Upregulation of BNIP3 by 5-aza-2'-deoxycytidine sensitizes pancreatic cancer cells to hypoxia-mediated cell death. J. Gastroenterol. 2005, 40:504-510.
19. Karpf A.R., Moore B.C., Ririe T.O., Jones D.A. Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2'-deoxycytidine. Mol. Pharmacol. 2001, 59:751-757.
20. Pulukuri S.M., Rao J.S. Activation of p53/p21Waf1/Cip1 pathway by 5-aza-2'-deoxycytidine inhibits cell proliferation, induces pro-apoptotic genes and mitogen-activated protein kinases in human prostate cancer cells. Int. J. Oncol. 2005, 26:863-871.
21. Steiner M.S., Wang Y., Zhang Y., Zhang X., Lu Y. P16/MTS1/INK4A suppresses prostate cancer by both pRb dependent and independent pathways. Oncogene 2000, 19:1297-1306.
22. Takeshima H., Ushijima T. Methylation destiny: moira takes account of histones and RNA polymerase II. Epigenetics 2010, 5:89-95.
23. Tanaka K., Imoto I., Inoue J., Kozaki K., Tsuda H., Shimada Y., Aiko S., Yoshizumi Y., Iwai T., Kawano T., Inazawa J. Frequent methylation-associated silencing of a candidate tumor-suppressor, CRABP1, in esophageal squamous-cell carcinoma. Oncogene 2007, 26:6456-6468.
24. Yagi K., Akagi K., Hayashi H., Nagae G., Tsuji S., Isagawa T., Midorikawa Y., Nishimura Y., Sakamoto H., Seto Y., Aburatani H., Kaneda A. Three DNA methylation epigenotypes in human colorectal cancer. Clin. Cancer Res. 2009, 16:21-33.
25. Abbas T., Dutta A. P21 in cancer: intricate networks and multiple activities. Nat. Rev. Cancer 2009, 9:400-414.
26. Seo H.S., Ju J.H., Jang K., Shin I. Induction of apoptotic cell death by phytoestrogens by up-regulating the levels of phospho-p53 and p21 in normal and malignant estrogen receptor alpha-negative breast cells. Nutr Res 2011, 31:139-146.
27. Takeshima H., Yamashita S., Shimazu T., Ushijima T. Effects of genome architecture and epigenetic factors on susceptibility of promoter CpG islands to aberrant DNA methylation induction. Genomics 2011, 98:182-188.
28. Kaneda A., Kaminishi M., Sugimura T., Ushijima T. Decreased expression of the seven ARP2/3 complex genes in human gastric cancers. Cancer Lett. 2004, 212:203-210.
29. Niwa T., Tsukamoto T., Toyoda T., Mori A., Tanaka H., Maekita T., Ichinose M., Tatematsu M., Ushijima T. Inflammatory processes triggered by Helicobacter pylori infection cause aberrant DNA methylation in gastric epithelial cells. Cancer Res 2010, 70:1430-1440.
30. Weisenberger D.J., Campan M., Long T.I., Kim M., Woods C., Fiala E., Ehrlich M., Laird P.W. Analysis of repetitive element DNA methylation by MethyLight. Nucleic Acids Res. 2005, 33:6823-6836.
31. Nakajima T., Yamashita S., Maekita T., Niwa T., Nakazawa K., Ushijima T. The presence of a methylation fingerprint of Helicobacter pylori infection in human gastric mucosae. Int. J. Cancer 2009, 124:905-910.
32. Naito Y., Yoshimura J., Morishita S., Ui-Tei K. SiDirect 2.0: updated software for designing functional siRNA with reduced seed-dependent off-target effect. BMC Bioinformatics 2009, 10:392.
33. Dworkin A.M., Huang T.H., Toland A.E. Epigenetic alterations in the breast: implications for breast cancer detection, prognosis and treatment. Semin. Cancer Biol. 2009, 19:165-171.
34. Esteller M., Guo M., Moreno V., Peinado M.A., Capella G., Galm O., Baylin S.B., Herman J.G. Hypermethylation-associated Inactivation of the cellular retinol-binding-protein 1 gene in human cancer. Cancer Res. 2002, 62:5902-5905.
35. Farias E.F., Ong D.E., Ghyselinck N.B., Nakajo S., Kuppumbatti Y.S., Mira y Lopez R. Cellular retinol-binding protein I, a regulator of breast epithelial retinoic acid receptor activity, cell differentiation, and tumorigenicity. J. Natl. Cancer Inst. 2005, 97:21-29.
36. Maass N., Biallek M., Rosel F., Schem C., Ohike N., Zhang M., Jonat W., Nagasaki K. Hypermethylation and histone deacetylation lead to silencing of the maspin gene in human breast cancer. Biochem. Biophys. Res. Commun. 2002, 297:125-128.
37. Raman V., Martensen S.A., Reisman D., Evron E., Odenwald W.F., Jaffee E., Marks J., Sukumar S. Compromised HOXA5 function can limit p53 expression in human breast tumours. Nature 2000, 405:974-978.
38. Silva J., Silva J.M., Dominguez G., Garcia J.M., Cantos B., Rodriguez R., Larrondo F.J., Provencio M., Espana P., Bonilla F. Concomitant expression of p16INK4a and p14ARF in primary breast cancer and analysis of inactivation mechanisms. J. Pathol. 2003, 199:289-297.
39. Morris M.R., Ricketts C.J., Gentle D., McRonald F., Carli N., Khalili H., Brown M., Kishida T., Yao M., Banks R.E., Clarke N., Latif F., Maher E.R. Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma. Oncogene 2010, 30:1390-1401.
40. Time for the epigenome. Nature 463 (2010) 587.
41. Zeitlinger J., Stark A., Kellis M., Hong J.W., Nechaev S., Adelman K., Levine M., Young R.A. RNA polymerase stalling at developmental control genes in the Drosophila melanogaster embryo. Nat. Genet. 2007, 39:1512-1516.
42. Sekimizu K., Nishioka N., Sasaki H., Takeda H., Karlstrom R.O., Kawakami A. The zebrafish iguana locus encodes Dzip1, a novel zinc-finger protein required for proper regulation of Hedgehog signaling. Development 2004, 131:2521-2532.
43. Wolff C., Roy S., Lewis K.E., Schauerte H., Joerg-Rauch G., Kirn A., Weiler C., Geisler R., Haffter P., Ingham P.W. Iguana encodes a novel zinc-finger protein with coiled-coil domains essential for Hedgehog signal transduction in the zebrafish embryo. Genes Dev. 2004, 18:1565-1576.
44. Berman D.M., Karhadkar S.S., Maitra A., Montes De Oca R., Gerstenblith M.R., Briggs K., Parker A.R., Shimada Y., Eshleman J.R., Watkins D.N., Beachy P.A. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 2003, 425:846-851.
45. Gupta S., Takebe N., Lorusso P. Targeting the Hedgehog pathway in cancer. Ther. Adv. Med. Oncol. 2011, 2:237-250.
46. Hatsell S., Frost A.R. Hedgehog signaling in mammary gland development and breast cancer. J. Mammary Gland Biol. Neoplasia 2007, 12:163-173.
47. Karhadkar S.S., Bova G.S., Abdallah N., Dhara S., Gardner D., Maitra A., Isaacs J.T., Berman D.M., Beachy P.A. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 2004, 431:707-712.
48. Kubo M., Nakamura M., Tasaki A., Yamanaka N., Nakashima H., Nomura M., Kuroki S., Katano M. Hedgehog signaling pathway is a new therapeutic target for patients with breast cancer. Cancer Res. 2004, 64:6071-6074.
49. Thayer S.P., di Magliano M.P., Heiser P.W., Nielsen C.M., Roberts D.J., Lauwers G.Y., Qi Y.P., Gysin S., Fernandez-del Castillo C., Yajnik V., Antoniu B., McMahon M., Warshaw A.L., Hebrok M. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003, 425:851-856.
50. Wang L.H., Choi Y.L., Hua X.Y., Shin Y.K., Song Y.J., Youn S.J., Yun H.Y., Park S.M., Kim W.J., Kim H.J., Choi J.S., Kim S.H. Increased expression of sonic hedgehog and altered methylation of its promoter region in gastric cancer and its related lesions. Mod. Pathol. 2006, 19:675-683.
51. Watkins D.N., Berman D.M., Burkholder S.G., Wang B., Beachy P.A., Baylin S.B. Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature 2003, 422:313-317.
52. Vokes S.A., McMahon A.P. Hedgehog signaling: iguana debuts as a nuclear gatekeeper. Curr. Biol. 2004, 14:R668-670.
53. Domann F.E., Rice J.C., Hendrix M.J., Futscher B.W. Epigenetic silencing of maspin gene expression in human breast cancers. Int. J. Cancer 2000, 85:805-810.
54. van Engeland M., Roemen G.M., Brink M., Pachen M.M., Weijenberg M.P., de Bruine A.P., Arends J.W., van den Brandt P.A., de Goeij A.F., Herman J.G. K-ras mutations and RASSF1A promoter methylation in colorectal cancer. Oncogene 2002, 21:3792-3795.
55. Wagner K.J., Cooper W.N., Grundy R.G., Caldwell G., Jones C., Wadey R.B., Morton D., Schofield P.N., Reik W., Latif F., Maher E.R. Frequent RASSF1A tumour suppressor gene promoter methylation in Wilms' tumour and colorectal cancer. Oncogene 2002, 21:7277-7282.
56. Dobrovic A., Simpfendorfer D. Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res. 1997, 57:3347-3350.
57. Esteller M., Silva J.M., Dominguez G., Bonilla F., Matias-Guiu X., Lerma E., Bussaglia E., Prat J., Harkes I.C., Repasky E.A., Gabrielson E., Schutte M., Baylin S.B., Herman J.G. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J. Natl. Cancer Inst. 2000, 92:564-569.
58. Xu X., Gammon M.D., Zhang Y., Bestor T.H., Zeisel S.H., Wetmur J.G., Wallenstein S., Bradshaw P.T., Garbowski G., Teitelbaum S.L., Neugut A.I., Santella R.M., Chen J. BRCA1 promoter methylation is associated with increased mortality among women with breast cancer. Breast Cancer Res. Treat. 2009, 115:397-404.
59. Wei M., Grushko T.A., Dignam J., Hagos F., Nanda R., Sveen L., Xu J., Fackenthal J., Tretiakova M., Das S., Olopade O.I. BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res. 2005, 65:10692-10699.